Gilead v. AbbVie: Who’s Winning the Hepatitis-C War?
January 30, 2015 at 12:49 PM EST
RBC’s Michael Yee and team think AbbVie’s (ABBV) update on its hepatitis-C treatment today is good news for Gilead Sciences (GILD). They explain why: Associated Press AbbVie said today on EPS call: 1) estimate at least $3B “run-rate” at YE:15 which to us implies around $750M+ in Q4:15, 2) estimate 175-215k GT1 pts are treated in [...]
